Approved for use by over 18 years of age despite German doubts
AstraZeneca raises controversy as it is expected to supply only 25% dose in the first quarter of this year
Third Corona 19 Vaccine Approved by EMA Following Pfizer and Modena Vaccines
The European Medicines Agency (EMA) approved the Oxford-AstraZeneca Corona 19 vaccine for use in all adult groups after days of suspicion, the British Guardian reported on the 29th (local time).
On the 30th, the global corona19 confirmed number exceeded 11636,000, and the death toll reached 2195,000.
One month after approval in the UK, EU regulators declared the vaccine safe for general use in 27 member states.
The vaccine is the third COVID-19 vaccine approved by EMA after Pfizer and Modena’s vaccine, both approved for all adults.
There has been concern that the lack of data on the effects of this vaccine on the elderly could lead to suspicion of approval for the elderly over the age of 65. Earlier this week, a committee of the Robert Koch Institute of the German Public Health Organization said that the vaccine could only be recommended for people aged 18 to 64 years old because there was insufficient data to judge.
AstraZeneca CEO Pascal Soriot said in a recent study by the company that it produced very potent antibodies to the virus in the elderly, similar to those found in young people, and British Prime Minister Boris Johnson said the vaccine was safe and triggered an immune response at all ages. I was confident.
Soriott welcomed the EMA’s decision, saying that the vaccine is not only effective and well tolerated, but also easy to manage and provides complete protection against serious illness and hospitalization.
The approval will now allow the deployment of 400 million doses ordered by the European Union for its population, the Guardian said. AstraZeneca warned the European Commission that it could supply only 25% of the expected dose in the first quarter of this year due to the low production volume at its Belgian plant, causing great controversy.
Many countries are struggling to vaccinate people as quickly as the UK, Israel, the United States and elsewhere, and long hoped the AstraZeneca vaccine would improve the situation.
In the meantime, the AstraZeneca vaccine has been approved for all adults in other countries, but only 12% of the study participants were over 55 years of age and enrolled later, so there was not enough time to get results.
A large trial released last month showed that the vaccine was about 70% effective in preventing disease caused by the coronavirus, but it is not known whether the vaccine could stop the spread of the disease.
A European Pharmacy official said, “The Human Medicines Commission has rigorously evaluated this vaccine, and the scientific basis of our work supports our firm commitment to protecting the health of the citizens of the European Union.”
Meanwhile, according to the Korea Centers for Disease Control and Prevention, the number of new corona 19 confirmed cases in Korea was 469 as of 0 o’clock on the 29th, and the number of severely ill patients decreased by 12 to a total of 239, and the number of deaths increased by 13 to a total of 1399.
Chemistry is everywhere. Copyright © Chemical News Unauthorized reproduction and redistribution prohibited